Şunu aradınız:: sammenligningsgruppen (Danca - İngilizce)

velcade i kombination med dexamethason) og patienter i sammenligningsgruppen (f.eks.
velcade in combination with dexamethasone) and patients in the comparison group (e.g.

sammenligningsgruppen i alle tre forsøg var ugentlig methotrexat (10- 25 mg ugentligt).
the comparator group in all three studies was weekly methotrexate (10-25 mg weekly).

totalt set rapporterede 99 ud af 8.956 patienter i vildagliptin-gruppen en hændelse versus 91 ud af 6.061 patienter i sammenligningsgruppen.
in total, 99 out of 8956 patients reported an event in the vildagliptin group vs 91 out of 6061 patients in the comparator group.

der var flere patienter i alpheon- gruppen end i sammenligningsgruppen, som fik tilbagefald af sygdommen efter behandlingens ophør, og alpheon gav flere bivirkninger.
however, some differences were seen between the two medicines: more patients experienced a return of the disease after treatment with alpheon was stopped than with the reference medicine, and there were more side effects with alpheon.

ved invasiv aspergillose var der ved behandlingens afslutning positiv reaktion hos 42 % af de patienter, der fik posaconazole sp, mod 26 % i sammenligningsgruppen.
in invasive aspergillosis, a successful response at the end of treatment was seen in 42% of the patients taking posaconazole sp, compared with 26% of the comparison group.

lonquex kunne også godt måle sig med det andet lægemiddel hvad angår antal tilfælde med febril neutropeni: der var 1 tilfælde i gruppen behandlet med lonquex, mod 3 tilfælde i sammenligningsgruppen.
lonquex also compared well with the other medicine in the number of febrile neutropenia cases: 1 in the lonquex-treated group versus 3 in the comparator group.

ved invasiv aspergillose var der ved behandlingens afslutning positiv reaktion hos 42% af de patien - ter, der fik noxafil, mod 26% i sammenligningsgruppen.
in invasive aspergillosis, a successful response at the end of treatment was seen in 42% of the patients taking noxafil, compared with 26% of the comparison group.

hos kræftpatienter var posaconazole sp mere effektivt end fluconazol og itraconazol, idet infektion opstod hos 2 % af patienterne i posaconazole sp-gruppen og 8 % i sammenligningsgruppen.
the medicine was more effective than fluconazole or itraconazole in cancer patients, with 2% of patients developing an infection in the posaconazole sp group, and 8% in the comparator group.

i undersøgelserne af forebyggende anvendelse var posaconazole sp lige så effektivt som fluconazol hos stamcelletransplanterede patienter, hvor infektion opstod hos 5 % af patienterne i posaconazole sp-gruppen og 9 % i sammenligningsgruppen.
in the prevention studies, posaconazole sp was as effective as fluconazole in stem cell transplant patients, with 5% of patients developing an infection in the posaconazole sp group, and 9% in the comparator group.

i sammenligningsgrupperne medførte sulfonylurinstof givet som tillæg til metformin en gennemsnitlig vægtøgning på 1,3 kg, og metformin givet i tillæg til sulfonylurinstof medførte et gennemsnitligt vægttab på 1,0 kg.
in comparator groups addition of sulphonylurea to metformin resulted in a mean weight gain of 1.3 kg and addition of metformin to a sulphonylurea a mean weight loss of 1.0 kg.